

# Clavis Pharma AS Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

https://marketpublishers.com/r/C0AAE48ADA2BEN.html

Date: May 2025

Pages: 50

Price: US\$ 499.00 (Single User License)

ID: C0AAE48ADA2BEN

## **Abstracts**

Clavis Pharma AS Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Clavis Pharma AS and its competitors. This provides our Clients with a clear understanding of Clavis Pharma AS position in the <a href="Pharmaceuticals and Biotechnology">Pharmaceuticals and Biotechnology</a> Industry.

The report contains detailed information about Clavis Pharma AS that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.

Another part of the report is a SWOT-analysis carried out for Clavis Pharma AS. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.

The Clavis Pharma AS financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-



term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.

In the part that describes Clavis Pharma AS competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.

Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Clavis Pharma AS business.

#### **About Clavis Pharma AS**

Clavis Pharma ASA, a healthcare and clinical-stage pharmaceutical company, engages in the discovery and development of novel small molecule therapeutics for cancer and other unmet medical needs. It also engages in the development of new and improved pharmaceuticals based on its lipid vector technology (LVT). The company has three anticancer drugs in clinical development for various indications, and a pipeline of other drug candidates within oncology, virology, and anti-inflammatory diseases. Its products primarily include Elacytarabine, which is in the Phase II clinical trials for various solid tumor indications, as well as in Phase I/II clinical trials for the treatment of blood cancers, including leukemia; Intravenous CP-4126, a multicentre trial open to patients with any type of solid tumours that is in Phase I clinical trials; Oral CP-4126, an analogue of gemcitabine, which is Phase I clinical trial; and CP-4200, an epigenetic modulator that is in preclinical stage for the treatment of hematological malignancies, such as MDS and leukemia. The company's products also include CP-4010, an analogue of acyclovir that is in the Phase I clinical trial for the treatment of herpes labialis and herpes genitalis; and CP-4018, an analogue of gancyclovir, which is in the preclinical stage. In addition, its products comprise CP-4033, CP-4112, and CP-4114 that are the analogues of ribavirin, betamethason, and prednisolon respectively. The company has a collaboration agreement with Mount Sinai School of Medicine for the design and testing of new LVT based drug candidates for the treatment of cancer and



haematological malignancies. Clavis Pharma ASA was founded in 2001 and is headquartered in Oslo, Norway.

The above Company Fundamental Report is a half-ready report and contents are subject to change.

It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.



## **Contents**

#### RESEARCH METHODOLOGY

#### **DISCLAIMER**

#### 1. CLAVIS PHARMA AS COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

#### 2. CLAVIS PHARMA AS BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

#### 3. CLAVIS PHARMA AS SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

#### 4. CLAVIS PHARMA AS FINANCIAL ANALYSIS

- 4.1. Financial Statements
- 4.1.1. Income Statement
- 4.1.2. Balance Sheet
- 4.1.3. Cash Flow
- 4.2. Financial Ratios
- 4.2.1. Profitability
- 4.2.2. Margin Analysis



- 4.2.3. Asset Turnover
- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

#### 5. CLAVIS PHARMA AS COMPETITORS AND INDUSTRY ANALYSIS

- 5.1. Clavis Pharma AS Direct Competitors
- 5.2. Comparison of Clavis Pharma AS and Direct Competitors Financial Ratios
- 5.3. Comparison of Clavis Pharma AS and Direct Competitors Stock Charts
- 5.4. Clavis Pharma AS Industry Analysis
- 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  - 5.4.2. Clavis Pharma AS Industry Position Analysis

#### 6. CLAVIS PHARMA AS NEWS & EVENTS

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

#### 7. CLAVIS PHARMA AS EXPERTS REVIEW1

- 7.1. Experts Consensus
- 7.2. Experts Revisions

#### 8. CLAVIS PHARMA AS ENHANCED SWOT ANALYSIS<sup>2</sup>

## 9. NORWAY PESTEL ANALYSIS<sup>2</sup>

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors



## 10. CLAVIS PHARMA AS IFE, EFE, IE MATRICES<sup>2</sup>

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

# 11. CLAVIS PHARMA AS PORTER FIVE FORCES ANALYSIS<sup>2</sup>

#### 12. CLAVIS PHARMA AS VRIO ANALYSIS<sup>2</sup>

**APPENDIX: RATIO DEFINITIONS** 

#### **LIST OF FIGURES**

Clavis Pharma AS Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit

**Profit Margin Chart** 

**Operating Margin Chart** 

Return on Equity (ROE) Chart

Return on Assets (ROA) Chart

Debt to Equity Chart

**Current Ratio Chart** 

Clavis Pharma AS 1-year Stock Charts

Clavis Pharma AS 5-year Stock Charts

Clavis Pharma AS vs. Main Indexes 1-year Stock Chart

Clavis Pharma AS vs. Direct Competitors 1-year Stock Charts

Clavis Pharma AS Article Density Chart

The complete financial data is available for publicly traded companies.

<sup>1 –</sup> Data availability depends on company's security policy.

<sup>2 –</sup> These sections are available only when you purchase a report with appropriate additional types of analyses.



## **List Of Tables**

#### LIST OF TABLES

Clavis Pharma AS Key Facts

**Profitability** 

Management Effectiveness

Income Statement Key Figures

**Balance Sheet Key Figures** 

Cash Flow Statement Key Figures

Financial Performance Abbreviation Guide

Clavis Pharma AS Key Executives

Clavis Pharma AS Major Shareholders

Clavis Pharma AS History

Clavis Pharma AS Products

Revenues by Segment

Revenues by Region

Clavis Pharma AS Offices and Representations

Clavis Pharma AS SWOT Analysis

Yearly Income Statement Including Trends

Income Statement Latest 4 Quarters Including Trends

Yearly Balance Sheet Including Trends

Balance Sheet Latest 4 Quarters Including Trends

Yearly Cash Flow Including Trends

Cash Flow Latest 4 Quarters Including Trends

Clavis Pharma AS Profitability Ratios

Margin Analysis Ratios

**Asset Turnover Ratios** 

**Credit Ratios** 

Long-Term Solvency Ratios

Financial Ratios Growth Over Prior Year

Clavis Pharma AS Capital Market Snapshot

Clavis Pharma AS Direct Competitors Key Facts

**Direct Competitors Profitability Ratios** 

**Direct Competitors Margin Analysis Ratios** 

**Direct Competitors Asset Turnover Ratios** 

**Direct Competitors Credit Ratios** 

Direct Competitors Long-Term Solvency Ratios

Pharmaceuticals and Biotechnology Industry Statistics



Clavis Pharma AS Industry Position

Company vs. Industry Income Statement Analysis

Company vs. Industry Balance Sheet Analysis

Company vs. Industry Cash Flow Analysis

Company vs. Industry Ratios Comparison

Clavis Pharma AS Consensus Recommendations<sup>1</sup>

Analyst Recommendation Summary<sup>1</sup>

Price Target Summary<sup>1</sup>

Experts Recommendation Trends<sup>1</sup>

Revenue Estimates Analysis<sup>1</sup>

Earnings Estimates Analysis<sup>1</sup>

Historical Surprises<sup>1</sup>

Revenue Estimates Trend<sup>1</sup>

Earnings Estimates Trend<sup>1</sup>

Revenue Revisions<sup>1</sup>



## **ANALYSIS FEATURES**

#### **SWOT Analysis**

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

#### **Enhanced SWOT Analysis**

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

How to use the strengths to take advantage of the opportunities?

How to use the strengths to reduce likelihood and impact of the threats?

How to overcome the weaknesses that obstruct taking advantage of the opportunities?

How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

#### **PESTEL Analysis**

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.



## Key Factors Examined by PESTEL Analysis:

Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations' impact on the business?

Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence's degree?

Sociological – What cultural and societal aspects will work upon the demand for the business's products and operations?

Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?

Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?

Legal – What laws and legislation will exert influence on the style the business is carried out?

#### IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business's functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors



integrated into one suggestive model.

## **Porter Five Forces Analysis**

The Porter's five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

What composes a threat of substitute products and services?

Is there a threat of new competitors entering the market?

What is the intensity of competitive rivalry?

How big is the bargaining power of buyers?

How significant is the bargaining power of suppliers?

## **VRIO Analysis**

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company's resources and capabilities and bring them together into one aggregate table that includes:

Tangible resources

Financial

Physical

Technological

Organizational

Intangible resources

Human

Innovation and Creativity



# Reputation

# Organizational capabilities

The result of the analysis gives a clear picture of company's competitive and economic implications, answering the questions if the resources mentioned above are:

Valuable?
Rare?
Costly to imitate?
Organized properly?



### I would like to order

Product name: Clavis Pharma AS Fundamental Company Report Including Financial, SWOT,

Competitors and Industry Analysis

Product link: https://marketpublishers.com/r/C0AAE48ADA2BEN.html

Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/C0AAE48ADA2BEN.html">https://marketpublishers.com/r/C0AAE48ADA2BEN.html</a>